Nicholas Galakatos, Ph.D., has been Managing Director of Clarus Ventures since the firm's inception in 2005. He has more than 25 years of industry and investment experience in the healthcare sector. Dr. Galakatos previously worked as a General Partner at MPM Capital, and was Vice President of New Business at Millennium Pharmaceuticals (presently Takeda). During that time, he co-founded Millennium Predictive Medicine and TransForm Pharmaceuticals. Prior to Millennium, Dr. Galakatos was at Venrock Associates, where he focused on early-stage biotechnology investments, and was Head of Molecular Biology Research at Novartis.

He currently serves or has served on the board of directors of several biotechnology companies, including Aerovance, Aveo, Caliper, Critical Therapeutics, Link Medicine, Nanostring, Portola, Syrrx, Taligen, TransForm, Hypnion and Affymax. In addition, Dr. Galakatos is a member of the Director's Council of the Koch Institute at the Massachusetts Institute of Technology (MIT), and the Genetics Advisory Council at Harvard Medical School.

He received his Bachelor of Arts (B.A.) degree in Chemistry from Reed College, a Doctor of Philosophy (Ph.D.) degree in Organic Chemistry from MIT, and performed postdoctoral studies in Molecular Biology at Harvard Medical School.